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Control of calcium oxalate crystal structure and cell adherence by
urinary macromolecules. Crystal polymorphism is exhibited by calcium
oxalates in nephrolithiasis, and we have proposed that a shift in the
preferred crystalline form of calcium oxalate (CaOx) from monohydrate
(COM) to dihydrate (COD) induced by urinary macromolecules reduces
crystal attachment to epithelial cell surfaces, thus potentially inhibiting a
critical step in the genesis of kidney stones. We have tested the validity of
this hypothesis by studying both the binding of monohydrate and dihydrate
crystals to renal tubule cells and the effect of macromolecular urinary
solutes on crystal structure. Renal tubule cells grown in culture bound
50% more CaOx monohydrate than dihydrate crystals of comparable size.
The effects of macromolecules on the spontaneous nucleation of CaOx
were examined in HEPES-buffered saline solutions containing Ca21 and
C2O4
22 at physiologic concentrations and supersaturation. Many naturally
occurring macromolecules known to be inhibitors of crystallization, spe-
cifically osteopontin, nephrocalcin and urinary prothrombin fragment 1,
were found to favor the formation of calcium oxalate dihydrate in this in
vitro system, while other polymers did not affect CaOx crystal structure.
Thus, the natural defense against nephrolithiasis may include impeding
crystal attachment by an effect of macromolecular inhibitors on the
preferred CaOx crystal structure that forms in urine.
Nephrolithiasis continues to cause significant morbidity, with a
lifetime prevalence in white American men and women of 10%
and 5%, respectively [1]. The recurrence rate is about 50% in 5 to
10 years [2], with a moderate improvement in recurrence rate by
conventional therapies [3]. Design of more effective preventative
therapies will depend on identifying critical early steps in the
process that leads to symptomatic stone formation in the kidney.
These early steps have been considered to include crystal nucle-
ation, growth of individual crystals, crystal aggregation,and reten-
tion of crystals or crystal aggregates within the kidney.
Although, on average, stone formers have slightly greater levels
of supersaturation than non-stone formers, concentrations of
calcium and oxalate ions are quite variable in urine samples from
either population, and the distributions of supersaturations within
the two populations substantially overlap one another [4]. Thus,
supersaturation is a necessary, but not a sufficient, condition for
stone formation.
It has long been appreciated that the flow of urine through the
kidney places a time constraint on the stone forming process [5],
because small crystals can simply be flushed out of the kidney
before they become large enough to be entrapped physically in the
collecting system of the kidney or the ureters and cause symptom-
atic disease. The best current estimates from known urine flow
rates through the kidney and calcium oxalate (CaOx) crystalliza-
tion kinetics suggest that either crystal aggregation or attachment
of non-occluding crystals or both must occur to allow crystals to be
retained in the kidney and grow to a size that will cause symp-
tomatic stone disease [5–7].
About 70% of kidney stones are composed of CaOx. A study of
over 10,000 kidney stones from patients has shown that calcium
oxalate monohydrate (COM) occurs about twice as frequently as
calcium oxalate dihydrate (COD), although many stones contain
both crystal forms [8]. On the other hand, asymptomatic crystals
in urine are a common occurrence, even in many individuals who
do not form stones, and these crystals are usually COD [9, 10].
COM is known to have affinity for renal tubule cell surfaces [11],
and theoretical calculations suggest that COM may have a stron-
ger affinity for these cell membranes than COD [12]. We have
proposed that a change in CaOx crystal structure could affect the
formation of kidney stones by favoring the formation of COD, the
less adherent crystal, and that normal urine contains factors that
influence calcium oxalate crystal structure in the direction of
COD [13]. Biologic control of crystal morphology and structure is
well known in nature [14], a specific example being the role of
mollusk shell macromolecules in determining crystal structure of
calcium carbonate [15]. The current studies report results dem-
onstrating a greater degree of attachment to renal tubule cells in
culture of COM compared to COD. In addition, the presence of
some urinary macromoleular inhibitors of crystal growth results in
preferential crystallization of COD from supersaturated solutions
of CaCl2 and Na oxalate, rather than COM.
METHODS
Crystal-membrane binding studies were carried out following
methods described by Wiessner et al [16] and Riese et al [17].
Briefly, crystals of COM containing 14C-enriched oxalate ion were
prepared by precipitation from a 150 mM NaCl solution buffered
with 10 mM HEPES at pH 7.0, to which was added CaCl2 and
Na2
14C2O4 to bring initial concentrations to 10 mM. COD was
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obtained by including 5 mM MgCl2 in the above solution. Maxi-
mum linear dimensions of COM and COD crystals were approx-
imately the same, in the range of 2 to 4 microns. Inner medullary
collecting duct (IMCD) cells were isolated from the kidneys of
young male Sprague-Dawley rats and grown in primary culture on
microscope cover slips in Dulbecco’s modified Eagle media with
added F-12 (HAM) nutrient mixture, as described by Wiessner et
al [16]. Crystals suspended in a 10 mM HEPES, 150 mM NaCl
buffer were permitted to settle on the cover slips for 30 minutes.
While this time period is surely longer than the contact time of
crystals and cells in the nephron, it has proved satisfactory for
demonstrating differential attachment in previous studies [17–19].
After a standardized wash with the same buffer to remove
unattached crystals, the fraction of bound crystals was determined
by scintillation counting.
Crystal formation
Crystal formation studies were performed in a buffer containing
150 mM NaCl and 10 mM HEPES, titrated to pH 7.5. Solutions
were prepared by volumetric addition of a tenfold buffer stock
solution, 10 mM solutions of CaCl2 and Na2C2O4, and stock
solutions of the various macromolecules to sufficient deionized
water to make 5 ml of solution at the desired Ca and Ox
concentrations. The ratio of Ca:Ox did not, by itself, influence
crystal structure nor was significant aggregation observed in these
studies. All solutions were filtered through 0.2 mm filters prior to
use and were visually free of any particulates. Oxalate ion was
always added as the last component, after premixing the other
components. The solutions were vigorously shaken for 10 seconds,
and were then allowed to precipitate in a quiescent state (because
continuous stirring of the system causes the formation of calcium
oxalate trihydrate, a crystalline form is not found in human kidney
stones), at room temperature (22 6 2 C°), overnight, and in a
closed container. The system essentially achieved equilibrium
calcium and oxalate concentrations. Crystals were separated from
the media by filtration through 5 micron controlled pore, track-
etched polycarbonate membranes (PCTE, 13 mm diameter;
Poretics Corporation) in a Swinney filter holder. Filters were
removed from the holders while still wet, mounted on a micro-
scope slide with a drop of the supernatant solution and a cover
slip. The slides were examined immediately by optical microscopy
(Nikon Optiphot-2) for crystal identification. Fractions of COM
and COD were estimated from visual examination of the entire
slide. Crystal identities were confirmed by X-ray powder diffrac-
tion for representative samples, but no attempt was made to
quantitate the fractions of crystal types from powder diffraction
data. Because of limitations in the amount of macromolecules
available, the reactions did not produce sufficient crystal mass to
obtain estimates of the fractions of the two crystal structures that
were any more reliable than those obtained visually, by either
FTIR or X-ray powder diffraction [13].
All chemicals were obtained from Sigma, except for the human
Tamm-Horsfall protein (THP), which was from Biomedical Tech-
nologies, Inc. (Stoughton, MA, USA) and was purified from the
urine of a single individual. Osteopontin (OPN) was isolated from
media in which rat renal cortical tubule cells were grown in
primary culture, as previously described [20]. Samples of all four
fractions of nephrocalcin (Neph-A through Neph-D) from a
single human source were furnished by Dr. Y. Nakagawa (Uni-
versity of Chicago, Chicago, IL, USA) [21, 22] and were used as
received. Urinary prothrombin fragment 1 (UPTF1), from pooled
human urine, was kindly furnished by Dr. R. Ryall at Flinders
Medical Center (Bedford Park, Australia) [23–25] and was used
as received. Samples of the macromolecular mixtures from whole
urine were obtained from 24-hour urine samples from five normal
adults by coarse filtering to remove particulates, then dialyzing
using membranes with an 8 kDa cutoff, and lyophilizing measured
volumes. All the individuals from whom macromolecules were
isolated were men between the ages of 20 and 50 and had no
history of kidney stones.
RESULTS
The relative binding of COM and COD to IMCD cells in
culture was tested at five different densities of added crystals,
ranging from 0.05 to 1.25 mg/cm2, on each of three separate cell
preparations. The average mass of crystal attached versus mass of
crystal applied is shown in Figure 1 for both crystalline forms. The
quantity of crystal bound was significantly greater for COM than
COD for each loading condition tested except one (presumably
due to the usual variations between different culture groups).
Each data set demonstrates saturation behavior, as has been
observed in many previous crystal binding experiments [17, 18,
26]. About 50% more COM than COD appears to bind to the
IMCD cells for a given amount of added crystals.
Figure 2 shows a plot of the fraction of COD formed versus the
concentration of added polymer for OPN, Neph-A, and UPTF1,
all measured at a physiologically relevant condition of 4 mM
calcium and 0.4 mM oxalate. Similar results were obtained for
Neph-A and OPN at 1 mM calcium and 1 mM oxalate. This was
expected on the basis of earlier data for polyaspartic acid [13]. The
Fig. 1. Attachment of calcium oxalate crystal types to cultured inner
medullary collecting duct (IMCD) cells. Mass of crystal attached to the
membrane is plotted against the mass of crystal applied for both crystal
types: (F) calcium oxalate monohydrate (COM) and (f) calcium oxalate
dihydrate (COD). Values are means 6 SE of experiments performed using
four different culture groups. The asterisks indicate the pairs of data
where the average values are statistically different at the 95% confidence
level (P , 0.05). The points are connected to guide the eye.
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four fractions of nephrocalcin, A through D, were essentially
equivalent in their effect on crystal structure, and will not be
discussed individually. All three proteins exhibit behavior compa-
rable to that seen previously with other non-protein polymers or
small molecular weight inhibitors [13, 27], with an approximately
linear progression from COM in the absence of polymer to COD
at sufficiently high concentrations. By comparison, the macromo-
lecular mixtures from whole normal urine, when reconstituted in
an equivalent volume of solution at the same buffer conditions
used above with 1 mM calcium and 1 mM oxalate, yielded from
50% to 100% COD, inversely dependent on the 24-hour urine
volume collected; 50% COD from samples with a 24-hour vol-
ume . 3 liters and 100% COD from specimens with 24-hour total
volumes , 1 liter, presumably a consequence of a higher aggre-
gate concentration of inhibitors in the latter.
In Figure 2, it appears that OPN and UPTF1 were nearly
equally effective in influencing the crystal structure of CaOx
toward COD, while Neph-A was somewhat less effective. How-
ever, it is useful to consider the data for individual proteins in light
of their concentrations in normal urine samples. OPN was found
in rodent urine at concentrations of about 8 mg/ml [20] and in
human urine at about 4 mg/ml [28]. UPTF1 was found in human
urine at about 1 mg/ml) [23–25]. Nephrocalcin has been found in
human urine at 5 to 10 mg/ml, representing the total for the
mixture of all four fractions [29]. When normalized with respect to
typical urine concentrations, OPN and Neph-A achieved com-
plete COD formation at two to three times normal urine concen-
trations (OPN based on rodent normals; the origin of the protein
used in this study). UPTF1 reached the same limit, but only at
about 10 times normal concentration. Therefore, OPN and
Neph-A would likely play the dominant roles in crystal structure
determination, in vivo, while UPTF1 would make a relatively
smaller contribution.
Neph-A appeared to be comparable to UPTF1 and OPN in its
limiting behavior for producing COD formation, but it exhibited
a completely different behavior at low to intermediate concentra-
tions, suggesting a different interaction with the crystal surface.
An additional point, not shown by Figure 2, is that the COM
fraction at low concentrations of Neph-A (about 1 mg/ml) was
significantly transformed from the typical prismatic crystal seen in
Figure 3A to a form shown in Figure 3B, along with a small
fraction of typical octahedral COD crystals. The crystal structure
of this species was confirmed by powder diffraction of several of
these samples, which showed them to be principally COM with a
small fraction of COD. As near as can be determined visually,
these appear to be COM crystals with the usually elongated
{101} and {010} faces shortened, presumably by inhibition of
growth at the {011} faces of the crystal. At concentrations at or
greater than normal urine, the COM formed in the presence of
Neph-A was again morphologically comparable to that formed in
the absence of polymer. By comparison, the COM formed in the
presence of OPN and UPTF1 was unchanged from the crystals
seen in Figure 3A, at any concentration tested. The macromolec-
ular mixture found in the whole urine samples caused a different
morphologic change in COM, forming the characteristic dumb-
bell-shaped polycrystalline morphology observed in urine.
Other proteins that do not strongly affect crystallization kinetics
were found to have no effect on the crystal structure or morphol-
ogy at physiologic concentrations, yielding crystals that were
identical to those seen in the absence of these polymers. THP was
tested at 28 mg/ml, a concentration approximating that of human
urine [30], with no significant change in the crystal morphology.
human serum albumin (HSA) was tested at several concentrations
up to 10 mg/ml, typical of human urine [30], again showing no
effect on the crystals formed.
Chon-A was tested at several concentrations up to 10 mg/ml,
almost twice normal urine concentrations [31], with essentially no
effect on crystal structure or morphology. At some conditions
there was some enrichment of COD (up to 5% of the crystal mass)
compared to no added polymer, while other conditions, including
10 mg/ml, were pure COM with no structure or morphology
change.
DISCUSSION
In the current studies two types of crystal modification of
calcium oxalate (CaOx) have been observed. The first, denoted as
a structural change, describes the shift in the preferred form that
crystallizes in this system from calcium oxalate monohydrate
(COM) to calcium oxalate dihydrate (COD). The second, de-
noted as a morphological change, describes differences that we
have observed among forms crystallographically identified as
COM. Both sorts of alterations have been called polymorphism in
the crystal literature.
Crystal polymorphism is a well known phenomenon in nature.
Examples include the variation of calcium carbonate crystal forms
in different mollusk shells and the formation of oriented iron
oxide crystals of magnetite by magnetotactic bacteria [32]. In
Fig. 2. Effect of urinary macromolecules on crystal morphology. The
mass fraction of calcium oxalate dihydrate (COD) formed is plotted
against the concentration of inhibitor protein for osteopontin (OPN; F),
nephrocalcin-A (Neph-A; X), and urinary prothrombin fragment-1
(UPTF1; M). The fraction of COD was obtained by visual estimate using
optical microscopy to gauge crystal identity by morphology after exami-
nation of the entire sample. The uncertainty was estimated to be in the
range of 6 10% in the mid-range of fractions and drops to less than 1%
at the extremes. For Neph-A, the crystal morphology of COM was
affected by the presence of the protein (see Fig. 3) at concentrations of
about 1 mg/ml. All experiments shown here were performed at 4.0 mM
calcium and 0.4 mM oxalate ion concentrations. Many, but not all
conditions, were tested two or more times, due to the limited samples of
urinary macromolecules available.
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Fig. 3. Calcium oxalate crystal morphology without inhibitors (A) and in the presence of Neph-A (B). Solutions were initially 1.5 mM for both calcium
and oxalate; the concentration of Neph-A was 100 nM. Without inhibitors (A) the morphology is of typical COM; with Neph-A (B), there are some
octahedral crystals (large arrow) characteristic of COD and a larger fraction of cubic appearing crystals (small arrow), shown to be COM by X-ray
powder diffraction.
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these examples, the crystal structure and morphology appear to be
directed by the organic macromolecules, frequently proteins, that
are produced by these organisms [15]. The basis for these effects
have not been clarified.
Proteins affecting calcium carbonate polymorphism in mollusk
shells are polyanions, and many are rich in aspartic acid mono-
mers [14, 15, 33]. Some macromolecules that have been shown
previously to influence the crystal structure of CaOx in favor of
COD, specifically RNA, heparin [27] and polyaspartic acid itself
[13], are also polyanions. These macromolecules also share the
property of inhibiting CaOx crystallization kinetics [20]. The
macromolecules reported to affect crystal structure in the current
study, nephrocalcin, osteopontin, and crystal matrix protein (re-
cently identified as a fragment of prothrombin, designated
UPTF1), are among the better known protein inhibitors of CaOx
nucleation and growth [20–25]. These proteins contain polyan-
ionic regions, as well as having a net negative charge. Chondroitin
sulfate, however, is another anionic macromolecule, a glycosami-
noglycan, which is known to be an inhibitor of CaOx crystalliza-
tion and aggregation [34]. It, unlike the other kinetic inhibitors,
had little effect on calcium oxalate crystal structure or morphol-
ogy in this system. Consequently, kinetic inhibition may be
required for an effect on structure or morphology, but it is clearly
not sufficient.
Another anionic protein that has attracted considerable atten-
tion in urolithiasis research, Tamm-Horsfall protein (THP) [35],
has little effect on crystallization kinetics, but it does strongly
inhibit aggregation of COM crystals in vitro. In addition, human
serum albumin (HSA) is among the most abundant anionic
proteins in urine, but it appears to have relatively little effect on
CaOx crystallization kinetics [36]. Neither THP nor HSA signifi-
cantly affected crystal structure or morphology in the current
study. Consequently, net charge also cannot, by itself, be respon-
sible for these effects.
Neph-A causes predominantly a morphological change in COM
at low concentrations, but at higher concentrations, it only seems
to favor the structural change to COD. None of the other
individual macromolecules reported have any effect on COM
morphology. The mixture of components in normal urine exhibits
all three effects, kinetic inhibition as well as both structural and
morphological alterations, although the morphology change in
COM that was observed is different from that seen with Neph-A.
These data suggest that kinetic inhibition of crystallization is
the least selective property in this set of macromolecules, implying
that the macromolecule-crystal interaction is also least specific for
this effect. Conversely, the morphologic change in COM appears
to be the most selective property, suggesting the most structurally
specific protein-crystal interaction. The shift to COD favored by
some of these polymers being intermediate in selectivity and,
presumably, structural interaction.
The nature of macromolecule-crystal interaction that influences
crystal structure or morphology in a spontaneously nucleating
system is unknown. Changes solely in crystal morphology, such as
the effect of Neph-A on COM, are more likely to be due to
inhibition of crystal growth on faces that normally grow rapidly;
the resulting relatively larger growth of one or more of the other
crystal faces developing a new crystal shape [33]. The polymorphic
effects seen in mollusk shells, where crystal structure and orien-
tation are directed by the organic matrix, are strongly suggestive
of direct nucleation of a favored crystal structure on a template
provided by a macromolecule [15, 33]. It seems unlikely that the
less selective interaction represented by the shift from COM to
COD would be the result of a template effect that would be
expected to be highly specific. It also seems unlikely that all the
polyanions tested that favor COD formation could share a
common, large-scale structural similarity and, thereby, serve as a
template for the same, unfavorable crystal structure. Also, obser-
vations that RNA, heparin and some small molecules cause COD
formation emphasizes this point. Without more direct evidence,
however, the mechanism leading to crystal structure modification
seen with CaOx cannot be defined with certainty, although our
data suggest that the inhibitory mechanism is most likely, where
COD is formed as an alternative pathway to relieve the chemical
potential favoring crystallization.
The nature of the differential attachment of COM and COD to
cells has not been defined. Different forms of chemically similar
or identical crystals differ in their interaction with cells, for
example, one racemic form of calcium tartrate supports the
growth of cells in culture and the other form does not [37]. It is
unclear to which component or components of the cell surface
crystals attach. Data support a role for surface phospholipid head
groups, particularly phosphtidylserine or other anionic compo-
nents in the case of COM [37, 38]. In this regard, it may be
significant that the number of dimensional matches between the
crystal structure and a repeating lattice of membrane phospholip-
ids headgroups is very much higher for COM than COD [12]. It
also may be relevant that the binding of COD to BSC-1 cells may
be initiated at the {100} face of the crystal [38]. This is a face that
accounts for a relatively small proportion of the surface area of
COD.
In summary, known urinary protein inhibitors of calcium ox-
alate crystallization have a substantial influence on the structure
of the CaOx crystal formed and tend to favor COD formation in
preference to COM. Several of these proteins independently exert
this influence on the crystal formed at physiologically relevant
concentrations, although the nature of the interaction remains
uncertain. The significance of this effect is suggested by the results
of crystal binding to cells in culture, where forming COD offers a
potential biological advantage in reduced affinity for the IMCD
cell membrane surface, the region of the collecting system where
symptomatic stones probably form. In addition, effects on COM
morphology were also observed, urine macromolecules resulting
in the dumbbell-shaped polycrystalline morphology usually ob-
served in urine and Neph-A inducing a shortening of the usual
long axis of typical COM crystals at low concentrations, but their
significance in stone disease is unknown and untested. While the
process of stone formation is certainly multifactorial, critical steps
in the process must be identified to propose effective therapeutic
mechanisms. These data suggest that some urinary components
may not only influence the development of kidney stones by
inhibiting nucleation or stone constituent crystal growth, but that
they may also interfere with crystal attachment by altering the
structure of crystals formed in urine in favor of a structure that
adheres less well to cells.
ACKNOWLEDGMENTS
This work was supported by grants DK48504 (J.G.K.) and DK30579
(N.S.M.) from the NIDDK, National Institutes of Health, and a Merit
Review Program (N.S.M.) from the Department of Veterans Affairs. We
Wesson et al: Control of calcium oxalate crystal structure956
gratefully acknowledge the technical assistance of Ann Beshensky, Linda
Hung, and Kathy Fryjoff.
APPENDIX
Abbreviations used in this article are: CaOx, calcium oxalate; COD,
calcium dihydrate; COM, calcium monohydrate; HSA, human serum
albumin; IMCD, inner medullary collecting duct; Neph-A through
Neph-D, four fractions of nephrocalcin; OPN, osteopontin; PCTE, track-
edged polycarbonate membranes; THP, Tamm-Horsfall protein; UPTF1,
urinary prothrombin fragment-1.
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